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Abstract
Background: Currently available treatments for colorectal cancer (CRC) associate with numerous side-effects that
reduce patients’ quality of life. The effective nutraceuticals with high anti-proliferative efficacy and low side-effects
are desirable. Our previous study has reported that free fatty acids extract (FFAE) of krill oil induced apoptosis of
CRC cells, possibly associated with changes in mitochondrial membrane potential (MMP). The aims of this study
were to compare the anti-proliferative efficacy of FFAE from krill oil on CRC cells with commonly used
chemotherapeutic drug, Oxaliplatin, and to investigate the molecular mechanisms underlying the anti-proliferative
effects of krill oil with a focus on intrinsic mitochondrial death pathway.
Methods: Three human CRC cell lines, including DLD-1, HT-29 and LIM-2405, and one mouse CRC cell line, CT-26,
were treated with FFAE of KO and the bioactive components of krill oil, eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) for 24 h and 48 h. Similarly, these cell lines were treated with Oxaliplatin, a commonly
used drug for CRC treatment, for 24 h. The effects of FFAE of KO, EPA, DHA and Oxaliplatin on cell proliferation,
mitochondrial membrane potential and reactive oxygen species (ROS) were determined via WST-1, JC-10, and ROS
assays respectively. The expression of caspase-3, caspase-9 and DNA damage following treatments of FFAE of KO was
investigated via western blotting and immunohistochemistry.
Results: The FFAE of KO, EPA and DHA significantly inhibited cell proliferation and increased formation of ROS in all
four cell lines (P < 0.01). A small dose of FFAE from KO ranged from 0.06 μL/100 μL to 0.12 μL/100 μL containing low
concentrations of EPA (0.13–0.52 μM) and DHA (0.06–0.26 μM) achieved similar anti-proliferative effect as Oxaliplatin
(P > 0.05). Treatments with the FFAE of KO, EPA and DHA (2:1 ratio) resulted in a significant increase in the
mitochondrial membrane potential (P < 0.001). Furthermore, the expression of active forms of caspase-3 and caspase-9
was significantly increased following the treatment of FFAE of KO.
Conclusions: The present study has demonstrated that the anti-proliferative effects of krill oil on CRC cells are
comparable with that of Oxaliplatin, and its anti-proliferative property is associated with the activation of caspase 3/9 in
the CRC cells.
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Introduction
Colorectal cancer (CRC) is the third most common can-
cer diagnosed and the fourth leading cause of cancer-re-
lated death affecting both men and women worldwide
[1, 2]. The initiation of CRC is a complex and multifac-
torial process that involves progressive accumulation of
genetic and epigenetic alterations, and these cause the
normal colonic/rectal mucosa transformation into inva-
sive metastatic carcinoma [3, 4] The risk factors associ-
ated with the development of CRC include consumption
of processed and red meat, sedentary life style, obesity,
smoking and alcohol intake [5, 6]. Currently available
treatments for CRC include surgery, chemotherapy and
radiotherapy [7], with surgery being more effective when
the disease is diagnosed at the early stage. However, in
most cases CRC is diagnosed at the advanced stages (III or
IV) when tumour has already spread to other parts of the
body [8]. The available treatments for the later stages of
CRC are chemotherapy and radiotherapy, which have nu-
merous side-effects that impact patient’s quality of life [9,
10]. In recent years more attention has been devoted to
nutraceuticals as alternative and/or conjunctive thera-
peutic agents for cancer prevention and treatment [10, 11].
Long chain omega-3 poly unsaturated fatty acids (LC
n-3 PUFA), eicosapentaenoic acid (EPA, 20:5n-3) and
docosahexaenoic acid (DHA, 22:6n-3), derived from fish
and other seafood, have been reported to inhibit the pro-
liferation and development of several cancers including
the CRC [12, 13]. Epidemiological studies have shown
that populations consuming large amounts of LC n-3
PUFA-rich fish oil have a lower risk of CRC [14]. In
vitro studies have found that EPA and DHA exert their
effects on cancer cells via several mechanisms including
changing the membrane composition, altering intracellu-
lar Ca++ concentrations as well as intracellular pH,
modifying mitochondrial membrane potential/perme-
ability, changing cellular resistance to ROS damage, and
by direct actions on DNA and gene expression [15–23].
Animal studies have also shown that fish oil supplemen-
tation reduced the number and size of tumours, angio-
genesis and metastasis [24–28].
Human consumption of fish-derived food products
has increased steadily, and the global capture of fish will
become un-sustainable in the future. Krill, a shrimp-like
marine zooplankton, has been identified as an alternative
source due to its wide and abundant distribution [29].
The main commercially available krill oil is extracted
from Antarctic krill (Euphasia superba), living in the
Southern Ocean, and it has become an important source
of LC n-3 PUFA in the last decades [29]. One of the ad-
vantages of krill oil compared to fish oil is that it has a
high concentration of phospholipids and krill oil derived
EPA and DHA are mainly bound to those lipids, pre-
dominantly phosphatidylcholine [29, 30] while in the fish
oil they are bound to the triglycerides [31, 32]. Previous
studies have suggested that the LC n-3 PUFA from
phospholipids may penetrate through the cell membrane
more efficiently, therefore lead to a higher bioavailability
[32] and more health benefits.
To date, only few in vitro studies have investigated the
anti-proliferative effect of krill oil [11, 33, 34], Su et al.
[11] have reported that krill oil inhibited cell prolifera-
tion in 43B and SJSA-1osteosarcoma cells. Zhu et al.
[33] have shown the inhibitory effects of krill oil on SW-
480 CRC cell line. In the previous study, we have
observed that FFAE of krill oil significantly inhibited the
proliferation and induced apoptosis of human CRC cell
lines HCT-15, SW-480 and Caco-2 [34]. We also found
that the pro-apoptotic property of krill oil may be
related to the increase in mitochondrial membrane po-
tential (MMP) [34]. Based on these findings, we hypoth-
esized that change in MMP of CRC cells following the
treatment with krill oil would cause the release of cyto-
chrome c. That would then activate caspase-9 and cas-
pase-3 and lead to nuclear DNA damage thus apoptosis
of CRC cells. The aims of this study were to compare
the anti-proliferative efficacy of FFAE of krill oil on CRC
cells with a chemotherapeutic drug, Oxaliplatin, com-
monly used for CRC treatment. Furthermore, we investi-
gated the molecular mechanisms associated with the
anti-proliferative effects of krill oil, with a focus on in-
trinsic mitochondrial death pathway.
Materials and methods
Cell lines and culture conditions
The human colon adenocarcinoma cell lines DLD-1 and
HT-29; and mouse colon cancer cell line CT-26 were
obtained from the American Tissue Culture Collection
(ATCC), Manassas, VA,USA (Catalogue No.CCL-221,
HTB-38 and CRL-2638), and human colon cancer cell
line LIM-2405, was obtained from the Ludwig Institute
for Cancer Research, Melbourne, Australia (Catalogue
No.CBA-0165). All cell lines were maintained in
RPMI1640 medium (Sigma Aldrich, Castle Hill, NSW)
supplemented with foetal calf serum (FCS, 10%)
(Hyclone Quantum Scientific, Clayton South, VIC), glu-
tamine (10 mM), 4–2-hydroxyethyl-1-piperazineethane-
sulfonic acid, sodium pyruvate (10 mM) and penicillin
(100 U/mL)/ streptomycin (100 μg/mL) (Sigma Aldrich,
Castle Hill, NSW). Cells were grown at 37 °C in 5% CO2
humidified atmosphere. Exponentially growing cells that
were > 90% viable were used for assays.
Extraction of free fatty acids from krill oils and fatty acid
preparation
Free fatty acids were extracted from the krill oil (Swisse
Wellness Pty Ltd., Victoria, Australia) following the hy-
drolysis (saponification) method of Salimon et al. [35].
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The extracts were dissolved in 100% ethanol and stored
at -20 °C. The final treatment solutions contained < 0.1%
ethanol as a solvent. Individual EPA and DHA were pur-
chased from Nu-Chek-Prep, Elysian, USA (Catalogue
No. T-325 and A-662). Fatty acid solutions were made
up by dissolving the individual fatty acids in ethanol and
the final treatment solutions contained < 0.1% ethanol as
a solvent.
Cell proliferation assay
A water-soluble tetrazolium-1 (WST-1) assay kit (Roche
Diagnostics GmbH, Germany) was used to determine
the proliferative potential of cancer cells. Cells were
seeded and cultured at 1 × 104 cells per well in 96-well
plates for 24 h and then treated with EPA or DHA solu-
tions for 24 and 48 h or FFAE of krill oil for 24 h. All
treatments were performed in triplicates and the con-
centrations of EPA, DHA and Oxaliplatin were selected
based on their respective dose-response curves. Four
concentrations (50 μM, 100 μM, 200 μM and 250 μM) of
DHA and three concentrations (50 μM, 100 μM,
200 μM) of EPA were used. FFAE of KO were diluted in
ethanol at three concentrations: 0.03 μL, 0.06 μL and
0.12 μL/100 μL prior to the treatment and that equate to
the concentrations of EPA and DHA per 100 μL well at
0.13/0.06, 0.26/0.13 and 0.52/0.26 μM, respectively. In all
experiments, 0.1% ethanol was used as a vehicle control,
non-treated cells as a negative control, and Oxaliplatin
as a positive control.. The WST-1 reagent (10 μL) was
added to each well after respective treatment time point
and incubated at 37 °C for 1 h. Cell proliferation was
measured using a micro-plate reader (Varioskan Flash,
Thermo Scientific) at the absorbance of 450 nm. Each
experiment was repeated three times for each cell line.
Reactive oxygen species (ROS) assay
The generation of ROS in the mitochondria after each
treatment was assessed using MitoSOX™ Red mitochon-
drial superoxide (Invitrogen, Australia). The cells were
seeded in 96-well plates at a density of 5 × 104 cells/well.
Cells were treated by the FFAE of KO at 0.12 μL/100 μL
dilution, EPA at 200 μM and DHA at 250 μM respect-
ively for 24 h. A working solution of MitoSOX™ was pre-
pared fresh and diluted in the phosphate buffered saline
(PBS) in the dark. MitoSOX™ (100 μL) was added to each
well and cells were incubated at 37 °C for 40 mins in a
shaker with gently shaking (Unimax 1010). The fluores-
cence intensity was measured using a microplate reader
(Varioskan Flash, Thermo Scientific) at excitation/emis-
sion (Ex/Em) wavelengths 495/525 nm and Ex/Em 490/
595 nm. The amount of ROS generated in the mitochon-
dria was measured as a ratio of aggregate (Em 525 nm)
to monomeric forms (Em 595 nm) of MitoSOX™. Three
replicates for each treatment and two individual experi-
ments were performed.
Mitochondrial membrane potential (MMP) JC-10 assay
Cells were seeded at 5 × 104 cells/well in clear bottom 96-
well plates (Corning TM Costar TM 3603, USA) and in-
cubated for at 37 °C for 24 h prior to undergoing the fol-
lowing treatments for 24 h: EPA at 200 μM, DHA at
250 μM, FFAE of KO at 0.12 μL/100 μL and six combina-
tions of EPA and DHA in a ratio of 1:1 and 2:1 at the con-
centrations of 50 μM, 100 μM, 200 μM of EPA and DHA
(for example, three mixtures of a ratio of 1:1 containing
50 μL EPA and 50 μL DHA at concentrations of 50 μM or
100 μM, or 200 μM. Similarly, a 2:1 ratio containing
66.67 μL of EPA and 33.33 μL of DHA at concentrations
of 50 μM or 100 μM, or 200 μM). The final volume of the
combined mixture was 100 μL. The MMP was measured
using the JC-10 assay kit (ab 112,134, Abcam, Australia)
as per the manufacturer’s instructions. Briefly, 50 μL of
JC-10 reagent was added to each well after the treatment
and incubated at 37 °C for 1 h in the dark. Thereafter,
50 μL of assay buffer B was added. Fluorescent intensity
was measured using a microplate reader (Varioskan Flash,
Thermo Scientific) at Ex/Em = 485/520 nm and Ex/Em =
540/570 nm. The change of mitochondrial membrane po-
tential was measured as the ratio of aggregate (Em 520
nm) to monomeric forms (Em 570 nm) of JC-10. The in-
crease in the ratio indicates the mitochondrial membrane
depolarisation. Three replicates were performed for each
treatment. The results were verified through at least three
individual experiments.
Immunocytochemistry
Cells were grown on chamber slides (Ibidi, Australia) at
a density of 1 × 104 cells/well in 8-well plates and incu-
bated at 37 °C in a 5% CO2 environment for 24 h. They
were then treated with the FFAE of KO at 0.12 μL/
100 μL for 8 h. Cells were fixed with 4% paraformalde-
hyde for 10 mins before permeabilizing for 15 mins with
0.1% Triton X-100 PBS. The donkey serum (10%) in
PBST was added before incubation at room temperature
for 1 h to block the endogenous activity. Then CRC cells
were incubated at 4 °C overnight followed by staining
with the primary antibodies for cleaved caspase-3 (1:500,
rabbit mAb 9664 (ASP 175 (5A 1E), Cell Signalling
Technologies, MA, USA) and for the DNA/RNA damage
(1:500, mouse monoclonal anti-DNA/RNA damage anti-
body (15A3), Abcam, MA, USA). The expression of
cleaved caspase-9 was investigated by staining with
rabbit anti- cleaved caspase-9 mAb [1:500 (ASP 330 -
E5Z7N), Cell Signalling Technologies, MA, USA]. The
cells were washed with PBS (3 × 10 mins) before incu-
bating with secondary antibodies (diluted to 1:250) la-
belled with different fluorophores: Alexa Fluor 594-
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conjugated donkey anti-rabbit (Jackson Immuno Re-
search Laboratories, PA USA) and Alexa Fluor 488-con-
jugated donkey anti-mouse (Jackson Immuno Research
Laboratories, PA USA) at room temperature for 2 h. All
these antibodies have been diluted in PBS with 2% don-
key serum and 0.01% Triton X-100. Then the cells were
washed with PBS 3 × 10 mins and incubated for 2 mins
with the fluorescent nucleic acid stain, 4′-6-diamidino-
2-phenylindole (DAPI). Finally, all cells were washed
with PBS for 10 mins before mounting on the fluores-
cent mounting medium (DAKO, USA). Cell images were
taken with the Eclipse Ti confocal laser scanning system
(Nikon, Tokyo, Japan). The excitation wavelengths for
FITC and Alexa Fluor 594 were adjusted to 488 nm and
559 nm respectively. Each fluorophore was measured
using 8 images taken at 20x magnification with a total
area of 2 mm2. All images were then calibrated to
standardize for a minimum basal fluorescence and con-
verted to binary. Fluorescence intensity was measured
using Image J software (National Institute of Health,
USA). The results were verified through at least three in-
dividual experiments.
Western blot
The expression of pro and active caspase-3 and caspase-9
proteins were investigated in two cell lines, DLD-1 and
HT-29. Cells were treated by FFAE of KO at 0.03 μL and
0.12 μL for 1 h, 4 h, 8 h and 12 h and the results were com-
pared with the ethanol control. After the treatment, cells
were collected and lysed in the radioimmunoprecipitation
assay buffer (RIPA buffer) (pH 7.4, 150mM NaCl, 0.1%
SDS, 0.5% sodium deoxycholate, 1% NP-40 in PBS, Sigma)
containing a protease and phosphatase inhibitors cocktail
(Roche Applied Science, USA). Cellular proteins (12 μg)
from each sample were separated using 4 to 20% sodium
dodecyl sulphate (SDS)/polyacrylamide gel electrophor-
esis. The separated fragments were transferred to 0.22 μm
polyvinylidene fluoride membranes, which were blocked
with 5% skim milk in PBST (0.1% Tween-20) by incubat-
ing at room temperature for 90 mins in a 40 RPM speed
shaker. The membrane was allowed to react with primary
antibodies against caspase-3 (1:1000, rabbit, E87
(ab32351), Abcam, MA, USA) and caspase - 9 (1:1000,
rabbit E23 (ab32539), Abcam, MA, USA) overnight at
4 °C. Membrane was washed three times in PBST (0.1%
Tween-20) and incubated with secondary antibody goat
anti-rabbit IgG H&L horseradish peroxidase (HRP)
(Abcam, ab6721, MA, USA) at room temperature for 1 h.
Again, the membrane was washed three times in PBST
(0.1% Tween-20). Glyceraldehyde-3-phosphate de-hydro-
genase (GADPH) (Abcam, ab9485, MA, USA) was used as
the loading control. The protein detection was performed
using enhancing chemiluminescence reagents (Clarity™
Western ECL Substrate, Bio-Rad, USA).
Chemiluminescence signals were captured using the FU-
SION FX System (USA). The expression level of each pro-
tein was quantified using Fusion Capt advance FX7
software. The results were verified through at least three
individual experiments.
Statistical analysis
All data were analysed using SPSS 22 software (IBM,
USA). Mixed model ANOVA was used to determine the
significance between treatments. The significance of re-
peated measure at different time point was analysed using
one-way ANOVA. Post-hoc analysis was conducted using
Tukey HSD test for multiple comparisons. P < 0.05 was
considered as significant. The results were expressed as
mean ± SD in tables or mean ± SEM in figures.
Results
Effect of FFAE of krill oil on the proliferation of CRC cell
lines compared with Oxaliplatin
DLD-1, HT-29, LIM-2405 and CT-26 cancer cells were
treated with the FFAE of krill oil at the concentrations of
0.03 μL, 0.06 μL, and 0.12 μL/100 μL for 24 h. The cell
proliferation of treatment groups was compared to that of
ethanol (vehicle control) treated cells (Fig. 1). Treatments
with FFAE of krill oil at concentrations of 0.03–0.12 μL/
100 μL for 24 h have significantly reduced proliferation of
DLD-1 cells by 18.2 ± 7.5% (P < 0.05) and up to 95.2 ±
1.8% (P < 0.001). Treatment with lower doses of Oxalipla-
tin did not show significant effect on the highly resistant
DLD-1 cells while high dose of Oxaliplatin (300 μM) re-
duced cell proliferation by 88.5 ± 1.4% (P < 0.001) (Fig. 1a).
Similarly, FFAE of krill oil inhibited cell proliferation of
HT-29 and LIM-2405 cells following 24 h of treatment. At
the low dose (0.03 μL/100 μL) of krill oil FFAE, cell prolif-
eration of HT-29 and LIM-2405 reduced by 12.9 ± 1.7%
(P < 0.05) and 17.9 ± 1.5% (P < 0.05) respectively, com-
pared to vehicle control cells (Fig. 1b and c). The greatest
impact on proliferation was observed at the 0.12 μL/
100 μL dose of FFAE, with significant 95.9 ± 0.1% reduc-
tion for HT-29 cells (P < 0.001) and 97.7 ± 2.3% for LIM-
2405 cells (P < 0.001) (Fig. 1b and c). Treatment with Oxa-
liplatin at the concentrations of 20 μM and 160 μM for 24
h has resulted in significant inhibition of proliferation with
15.1 ± 0.9% and 87.1 ± 0.7% reductions for HT-29 cells
(Fig. 1b) and14.3 ± 4.4 (P < 0.05) and 94.1 ± 1.8 (P < 0.001)
reductions for LIM-2405 cells (Fig. 1c).
The CT-26 mouse CRC cells were more sensitive to krill
oil FFAE treatment, compared to human cell lines (Fig.
1d). The cell proliferation was reduced by 30.7 ± 0.4% (P <
0.01) at the 0.03 μL/100 μL concentration of krill oil FFAE,
and by 96.5 ± 0.8% (P < 0.001) at the 0.12 μL/100 μL con-
centration. These results were also comparable to the ef-
fects of Oxaliplatin treatments (Fig. 1d).
Jayathilake et al. Nutrition & Metabolism           (2019) 16:53 Page 4 of 15
AC
B
D
Fig. 1 Effects of FFAE of krill oil on the proliferation of CRC cells compared to the anti-cancer drug Oxaliplatin. Cell viability of DLD-1 (a), HT-29 (b),
LIM-2405 (c) and CT-26 (d) cells were determined using WST-1 assay following 24 h of treatment with FFAE of krill oil (KO) at the concentrations of
0.03 μL/100 μL (containing 0.13 μM EPA/0.065 μM DHA), 0.06 μL/100 μL (containing 0.26 μM EPA/0.13 μM DHA), and 0.12 μL/100 μL (containing 0.52 μM
EPA/0.26 μM DHA) or chemotherapeutic drug, Oxaliplatin (OXAL). The experiment was repeated three times for each cell line. Data are expressed as
mean ± SEM (n = 3), *p < 0.05, **p < 0.01 and ***p < 0.001 indicate a significant difference between the treatment and Ethanol (vehicle) control
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Effects of n-3 PUFA on cancer cell proliferation
The effects of n-3 PUFA, DHA and EPA, on prolifera-
tion of human colon cancer cells (DLD-1, HT-29 and
LIM-2405) and mouse colon cancer cell (CT-26) are
shown in Fig. 2. Both DHA and EPA have inhibited pro-
liferation of all four cell lines in a dose-dependent
manner.
DLD-1 cells treated with DHA and EPA at concentra-
tions less than 100 μM did not cause significant changes
in cell proliferation, compared to vehicle treated cells at
24 and 48 h time points (Fig. 2a). The 100 μM dose of
DHA reduced cell proliferation by 49.4 ± 3.2% (P < 0.01)
following 48 h of treatment. DHA treatments at 200 μM
and 250 μM concentrations significantly inhibited cell
proliferation by more than 95% at both time points (P <
0.001 for both). The low concentration of EPA (100 μM)
has resulted in significant reduction of cell proliferation
by 57.9 ± 0.9% at 24 h and 71.7 ± 1.5% at 48 h (P < 0.01
for both). Treatment with higher concentration of EPA
(200 μM) has inhibited cell proliferation by 98.5 ± 0.2%
at both time points (P < 0.001 for both).
Treatments with lower concentrations (50 μM and
100 μM) of both DHA and EPA have not shown signifi-
cant effects on HT-29 cells (Fig. 2b). Treatments with
200 μM and 250 μM of DHA reduced cell proliferation
by 89.8 ± 2.0% and 95.4 ± 0.4% respectively at 24 h and
98.2 ± 0.4% and 98.2 ± 0.2% at 48 h (P < 0.001 for all).
Treatment with 200 μM EPA inhibited cell proliferation
by 95.9 ± 0.6% at 24 h and 98.1 ± 0.1% at 48 h (P < 0.001
for both).
As shown in Fig. 2c, LIM-2405 cells treated with lower
concentrations (50–100 μM) of DHA have shown signifi-
cantly inhibited cell proliferation at both 24 and 48 h
(P < 0.05). Treatments with DHA at 200 μM and 250 μM
resulted in marked reduction of cell proliferation (93.4 ±
1.5% and 99.3 ± 0.1% respectively) (P < 0.001 for both).
Treatments with EPA at concentrations of 50–200 μM
have inhibited cell proliferation significantly (P < 0.05 for
all). Remarkable results were observed at the high con-
centration (200 μM) with a reduction of 97.7 ± 0.2% and
99.3 ± 0.1% cell proliferation being recorded at 24 and
48 h respectively (P < 0.001 for both).
The lower concentration of DHA (50 μM) did not
show significant effect on proliferation of CT-26 cells.
The proliferation of CT-26 cells was reduced signifi-
cantly by DHA at the concentrations of 200 μM and
250 μM (98.9 ± 0.1% - - 99.9 ± 0.7%) (P < 0.001 for all),
(Fig. 2d).
Treatments with 50 μM of EPA reduced the prolifera-
tion of CT-26 cells slightly at 48 h (P < 0.05) while
100 μM of EPA showed stronger inhibitory effect (P <
0.05). Treatment with 200 μM EPA inhibited most of cell
proliferation with a reduction of 96.9 ± 0.7% at 24 h and
99.2 ± 0.0% at 48 h (P < 0.001 for both).
Effect of FFAE of krill oil, EPA and DHA on ROS formation
The effects of FFAE of krill oil, EPA and DHA on ROS
formation in all four cell lines are shown in Fig. 3. After
24 h of KO treatment ROS production increased by ap-
proximately 30% across all CRC cell lines, compared to
the vehicle treated cells. Although to a less degree than
KO, both DHA and EPA resulted in similar trend of in-
creased ROS production with approximately 20–30% of
increase in all four cell lines following EPA treatment
and 20–25% increase following DHA treatment.
Effect of FFAE of krill oil, EPA and DHA on mitochondrial
membrane potential of cancer cells
Changes of mitochondrial membrane potential in all
four CRC cell lines following treatments by krill oil
FFAE at 0.12 μL/100 μL, DHA at 250 μM and EPA at
200 μM for 24 h are shown in Fig. 4a. Significant MMP
depolarisation was observed across cell lines following
the treatment with krill oil FFAE compared to the etha-
nol control (P < 0.001) (Fig. 4a). However, no significant
changes were observed following treatments by EPA or
DHA alone except in LIM-2405 cells (P < 0.001). There
were also no significant changes in MMP in any of the
four cell lines following 24 h of treatment with a mixture
of EPA and DHA in a volume ratio of 1:1 at the concen-
trations of 50 μM, 100 μM and 200 μM (data not shown).
However, a significant increase of MMP was observed in
all four CRC cell lines following treatments with com-
bined EPA and DHA in a volume ratio of 2:1 at the con-
centration of 200 μM (P < 0.01 for all). Treatments at
lower concentrations (50 μM and 100 μM) with 2:1 vol-
ume ratio of EPA and DHA did not have any significant
effect on MMP (Fig. 4b).
Expression of caspase-3 and caspase-9 levels following
treatments of FFAE from krill oil
The expression of caspase-3 and caspase-9 proteins was
investigated via western blotting and immunohistochem-
istry, and data from DLD-1 and HT-29 cells were shown
in Figs. 5 and 6. Low and high doses of krill oil FFAE
(0.03 μL/100 μL and 0.12 μL/100 μL) were selected for
treatments. The extraction of proteins was carried out at
2, 4, 8 and 12 h following treatments. The level of cas-
pase-3 and caspase-9 started to increase after 4 h of
treatment and declined after 12 h, therefore, only the re-
sults obtained from 4 and 8 h are presented.
The FFAE of krill oil has activated caspase-9 and re-
sulted in increase of cleaved caspase-9 in DLD-1 and
HT-29 cells at 4 and 8 h of treatments. DLD-1 cell line
treated by krill oil FFAE at the concentration of 0.03 μL/
100 μL and 0.12 μL/100 μL has shown an increase in the
protein expression by 6.8 and 22.2% at 4 h and 43.5
and 95.7% at 8 h respectively compared to ethanol
control (Fig. 5A). Similar increase in caspase-9 protein
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Fig. 2 (See legend on next page.)
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level was observed in HT-29 cells after treatment
with krill oil FFAE by 1.5 and 49.4% at 4 h and by
73.7 and 84.2% at 8 h respectively compared to etha-
nol control (Fig. 5A’). The immunohistochemistry re-
sults were consistent in both cell lines after 8 h of
treatment with 0.12 μL/100 μL of krill oil FFAE. A
significant increase in the fluorescence intensity of
cleaved caspase-9 was observed in both DLD-1 and
HT-29 cells following treatments with krill oil FFAE
compared to the ethanol control (P < 0.001) (Fig. 5B-B’).
The number of cells showing cleaved caspase-9 immuno-
fluorescence was higher in DLD-1 and HT-29 cells treated
with FFAE of krill oil compared with vehicle control group
(Fig. 5C-C’).
The FFAE of krill oil has activated caspase-3 and re-
sulted in increase of cleaved caspase-3 in both cell lines
in a similar way as to caspase-9. DLD-1 cells treated by
krill oil FFAE at the concentrations of 0.03 μL/100 μL
and 0.12 μL/100 μL have shown an increase in the ex-
pression of caspase-3 by 4.6 and 29.1% at 4 h and by
65.7 and 92.9% at 8 h respectively (Fig. 6A). Increased in
caspase-3 protein level was observed in HT-29 cells after
treatment with krill oil FFAE at the concentration of
0.03 μL/100 μL by 37.9% at 4 h and concentration of
0.12 μL/100 μL by 89.3% at 8 h (Fig. 6A’). These results
were further verified by the immunohistochemistry assay
(Figs. 6B-B’, C-C′).
The DNA damage following treatment with FFAE of
krill oil at a concentration of 0.12 μL/100 μL was also
assessed using immunohistochemistry (Fig. 6B-B’, C-C′).
It was found that the level of DNA damage was en-
hanced significantly (P < 0.001) in both DLD-1 and HT-
29 cell lines following treatments with FFAE of krill oil
for 8 h compared to ethanol control.
Discussion
The present study investigated the effects of krill oil
FFAE on human CRC cell lines DLD-1, HT-29, LIM-
2405 and a mouse CRC cell line CT-26. The results
demonstrated that krill oil FFAE significantly inhibited
the growth of all four cell lines and confirmed the anti-
proliferative property of krill oil on other CRC cell lines
and osteosarcoma previously reported by us [11, 34] and
others [33]. The anti-proliferative effects of krill oil
FFAE were similar to the effects of its bioactive constitu-
ents, EPA and DHA although the effective dose of krill
oil extract is much lower. This indicates that the anti-
proliferative properties of krill oil are attributed to EPA
and DHA. The reason that a lower dose of krill oil ex-
tract (0.13–0.52 μM EPA/0.065–0.26 μM DHA) achieved
similar effect as isolated EPA (50–200 μM) and DHA
(50–250 μM) may be related to the fact that krill oil con-
tains not only EPA and DHA but also a range of other
fatty acids including saturated fatty acids (SFA) and
monounsaturated fatty acids (MUFA), and the interac-
tions between SFA, MUFA and EPA and DHA may have
enhanced the efficacy of these n-3 fatty acids, as re-
ported by Dias et al. [36] and MacDonald-Wicks and
Garg [37]. In addition, we found that a relatively low
dose of krill oil FFAE could achieve a remarkable anti-
(See figure on previous page.)
Fig. 2 Proliferation of CRC cells following treatment with EPA and DHA. Cell viability of DLD-1 (a), HT-29 (b), LIM-2405 (c) and CT-26 (d) cells were
determined using WST-1 assay following treatment with DHA and EPA for 24 and 48 h. The experiment was repeated three times for each cell
line. Data are expressed as mean ± SEM (n = 3), *p < 0.05, **p < 0.01 and ***p < 0.001 indicate a significant difference between the treatment and
Ethanol (vehicle) control
Fig. 3 ROS formation in mitochondria of CRC cells after 24 h of treatment with FFAE of krill oil, EPA and DHA. The mitochondrial superoxide level
was measured using the MitoSox™ and was presented as a percentage comparison to the ROS level in Ethanol (vehicle) treated cells. Three
replicates for each treatment and two individual experiments were performed. Data are expressed as mean ± SEM (n = 3). **p < 0.01 indicates a
significant difference between the treatment and Ethanol (vehicle) control
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proliferative effect comparable with Oxaliplatin, a com-
monly used clinical drug for CRC treatment [38]. Fur-
thermore, this study provides evidence for the possible
mechanistic pathway involved in the anti-proliferative ef-
fects of krill oil. Mitochondria appear to be the main tar-
get of krill oil FFAE, and the change in MMP have
resulted in the activation of caspase-9 and caspase-3.
This then induced DNA damage leading to apoptosis
(Fig. 7).
Previous studies suggested that EPA and DHA, alone or
in combination, have the ability to suppress CRC through
changing the membrane fluidity, anti-inflammation and
altering signalling pathways involved in carcinogenesis,
angiogenesis and cell metastasis [39–42]. Several molecu-
lar mechanisms underlying the anti-cancer effect of these
fatty acids have been proposed. These include the inhib-
ition of cell proliferation and promotion of apoptosis
through the tumour suppressor (Hippo) pathway [13];
suppression of pro-inflammatory molecules, prostaglandin
PGE2, an eicosanoid derived from arachidonic acid (AA)
through the COX-2 pathway [43, 44]; promoting cell
death via altering the mitochondrial membrane potential
[19] and EGFR complex, as well as associated intracellular
signalling pathways involving ERK 1/ 2, and mechanistic
target rapamycin (mTOR) [45]. Furthermore, EPA and
DHA have been reported to downregulate anti-apoptotic
proteins and lead to the activation of caspase pathways
[46–49].
Caspases play a significant role in the apoptosis of can-
cer cells. These enzymes are activated through three
pathways including the extrinsic death receptor, intrinsic
mitochondrial, and intrinsic endoplasmic reticulum (ER)
death pathways [50–52]. The present study suggests that
the anti-proliferative property of krill oil is closely asso-
ciated with the intrinsic mitochondrial death pathway
initiated by changes in the MMP. This process involves
the change of mitochondrial outer membrane permeabil-
ity/depolarisation due to DNA damage or ROS accumu-
lation. Membrane depolarisation causes the release of
cytochrome c into the cytosol. The cytochrome c is in-
volved in the formation of pro-caspase-9 and apoptotic
protease activating factor-1 (APAF-1) complex that acti-
vate executioner caspase-3 or 7 through initiator cas-
pase-9 [52–55]. Previous studies have reported that the
A
B
Fig. 4 Mitochondrial membrane potential (MMP) in CRC cells following treatment with FFAE of krill oil, EPA and DHA. (a) MMP of DLD-1, HT-29, LIM-
2405 and CT-26 cells was measured using the JC-10 fluorescent MMP microplate assay following 24 h of treatment with FFAE of krill oil (0.12 μL/100 μL,
containing 0.52 μM EPA/0.26 μM DHA), DHA (250 μM) or EPA (200 μM). (b) Effects of treatment with combined EPA and DHA at a 2:1 volume ratio. Three
replicates for each treatment and two individual experiments were performed. Data are expressed as mean ± SEM (n = 3), **p < 0.01 and ***p < 0.001
indicate a significant difference compared to Ethanol (vehicle) control
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release of cytochrome c is associated with proteins of
Bcl-2 family involved in the signal transduction and
various cytotoxic stimuli [56]. The interaction of Bcl-
2 proteins regulates the integrity of outer mitochon-
drial membrane (OMM). The pro-apoptotic Bcl-2
proteins change the permeability of mitochondrial
membrane that allows the release of cytochrome c
from the mitochondrial intermembrane space into the
cytosol. Cytochrome c is directly involved in the acti-
vation of caspase-3 pathway via the apoptosome com-
plex that contains cytochrome c/APAF-1/caspase-9
[55]. The caspase-9 in the apoptosome complex re-
cruits caspase-3 into the apoptosome complex [57] to
produce many cellular and biochemical events in-
volved in apoptosis [58]. Therefore, the activation of
caspases is essential for cancer suppression [59]. The
present study has demonstrated the changes in the
MMP and activation of caspase-9 and caspase-3 in
CRC cells following the treatment of krill oil FFAE.
We also observed the significantly high level of DNA
damage in all four cell lines compared to ethanol
(control) treatment. This finding agrees with the
study by Giros et al. [19] demonstrating that EPA
and DHA induce apoptosis through the intrinsic
death pathway in colon cancer cells Caco-2, HT-29,
SW-480 and HCT-116.. The activation of intrinsic
A
B
A’
B’
C C’
Fig. 5 Activation of caspase-9 in CRC cells after treatment with FFAE of krill oil. The expression of caspase-9 and cleaved caspase-9 was measured by
western blotting in DLD-1 (A) and HT-29 (A’) cells following treatment with FFAE of krill oil at 0.03 μL/100 μL (containing 0.13 μM EPA/0.065 μM DHA)
and 0.12 μL/100 μL (containing 0.52 μM EPA/0.26 μM DHA) for 4 h and 8 h. Fluorescent intensity of subcellular distribution of cleaved caspase-9 in DLD-
1 (B-C) and HT-29 (B′-C′) cells was determined using a monoclonal antibody for cleaved caspase-9 following 8 h of treatment with FFAE of krill oil at
0.12 μL/100 μL(containing 0.52 μM EPA/0.26 μM DHA). Scale bar = 50 μM. Magnification = 60X. The results were verified through at least three
individual experiments. Data are expressed as mean ± SEM. ***p < 0.001 compared to Ethanol control
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pathway of apoptosis with EPA and DHA treatments
have also been reported in human neuroblastoma
cells [53] and in multiple myeloma cells [60].
The reactive oxygen species (ROS) have a dual role in
cancer development. On the one hand, ROS can pro-
mote pro-tumorigenic signalling, facilitating cancer cell
proliferation, survival, and adaptation to hypoxia. On the
other hand, ROS can promote anti-tumorigenic signal-
ling and trigger oxidative stress–induced cancer cell
death [61]. In the present study we found a significant
increase of ROS level in CRC cells following treatments
by the FFAE of krill oil, EPA and DHA correlated with
anti-proliferative effects. Furthermore, we have shown
that the FFAE of krill oil is more potent in increasing
ROS in the cancer cells than EPA or DHA alone (Fig. 3).
In agreement with our study, previous studies on human
non-small cell lung cancer (NSCLC) and prostate cancer
cell lines, PC3 and DU145, found that DHA induced cel-
lular apoptosis through the over-production of ROS in
the mitochondria, which caused inactivation of the
A
B
A’
B’
C C’
Fig. 6 Activation of caspase-3 in DLD-1 and HT-29 cells following treatment with FFAE of krill oil. The expression of caspase-3 and cleaved caspase-3 was
measured by western blotting in DLD-1 (A) and HT-29 (A’) following treatment with FFAE of krill oil at 0.03 μL/100 μL (containing 0.13 μM EPA/0.065 μM
DHA) and0.12 μL/100 μL (containing 0.52 μM EPA/0.26 μM DHA) for 4 h and 8 h. Fluorescent intensity of subcellular distribution of cleaved caspase-3 and
DNA damage in DLD-1 (B-C) and HT-29 (B′-C′) cells was determined using monoclonal antibodies for cleaved caspase-3 and DNA/RNA damage (anti-8-
OHdG) following 8 h of treatment with FFAE of krill oil at 0.12 μL/100 μL (containing 0.52 μM EPA/0.26 μM DHA) . Scale bar = 50 μM. Magnification = 60X.
The results were verified through at least three individual experiments. Data are expressed as mean ± SEM. **p < 0.01 and ***p < 0.001 compared to
Ethanol control
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PI3K/Akt pathway inhibiting growth and proliferation of
cancer cells [62, 63]. In addition, Kang et al. (2010) ob-
served that EPA and DHA increased production of ROS
that causes apoptosis of MCF-7 breast cancer cells [64].
ROS are produced in different subcellular regions by
the action of different enzymes [65]. Mitochondria pro-
duce a large amount of ROS as a by-product of fatty acid
metabolism and oxidative phosphorylation during the
synthesis of ATP [63, 66]. Our results have shown a sig-
nificant depolarization of mitochondrial membrane of
the CRC cells following the treatment of krill oil FFAE.
Furthermore, a combination of EPA and DHA at
200 μM in a ratio of 2:1 also resulted in a significant
depolarization of mitochondrial membrane while a com-
bination of EPA and DHA at 200 μM in 1:1 ratio has not
shown significant effect on the MMP. In our previous
study [34] we also observed a significant increase of
MMP in CRC cell lines HCT-15, SW-480 and Caco-2
after treatment by krill oil FFAE but not by EPA or
DHA alone. However, So et al. (2015) and Giros et al.
(2009) reported that EPA and DHA treatments alone at
the concentrations between 50 and 60 μM altered the
MMP and resulted in apoptosis of human neuroblast-
oma and CRC cell lines Caco-2, HT-29 and SW-480 [19,
67]. The discrepancy between our study and that by So
[67] and Giros et al. [19] could be due to the sensitivity
of different CRC cells. It is known that ROS production
during catabolism of long chain (LC) fatty acids may re-
flect a complex process. LC fatty acid-induced ROS
production at the physiological range of MMP and rela-
tive insensitivity to the changes of MMP has been previ-
ously reported [68]. A mitochondrial membrane
potential-independent ROS production has been ob-
served in brain mitochondria [69, 70]. Several factors
might contribute to the increased ROS production with-
out changes in MMP. LC fatty acid breakdown can gen-
erate intermediates and by-products that can inhibit the
mitochondrial electron transport chain to potentially
augment ROS production. The mitochondrial ROS load
also depends upon the activity of antioxidant processes. It
has been suggested that some components of the mito-
chondrial glutathione antioxidant system are inhibited
during LC fatty acid catabolism [68]. Further studies are
warranted to uncover the mechanisms of ROS production
following treatment of individual EPA and DHA.
Oxaliplatin is a commonly used chemotherapeutic
drug for patients with metastatic CRC (stage III and IV)
[71]. However, it has been reported to cause severe side-
effects including cytopenia, peripheral neurotoxicity,
nausea, vomiting, diarrhoea and constipation [72, 73].
The present study has demonstrated that the anti-prolif-
erative effects of krill oil on CRC cells are comparable
with that of Oxaliplatin. Based on the findings from this
study, the equivalent human dose of treatment would be
302.45 mg of EPA, and 328.48 mg of DHA. This is
equivalent to 4–5 krill oil capsules (1 g) daily. This dose
is feasible in practice. More importantly krill oil is safe
as no associated side-effects have been reported [29, 32].
Fig. 7 Schematic summary of the death signaling pathways initiated by the FFAE of krill oil in DLD-1 and HT-29 cells. The FFAE of krill oil and a
combination of EPA/DHA exert their effects on cancer cells by changing the mitochondrial membrane potential (MMP). That results in the
activation of caspase-9 and caspase-3 and lead to nuclear DNA damage hence possible apoptosis of cancer cells
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Conclusions
This study demonstrated that the FFAE of krill oil has a
remarkable anti-proliferative property, comparable with
that of Oxaliplatin. This is likely attributed to its bio-
active components, EPA and DHA. The pro-apoptotic
effects of krill oil, EPA and DHA on CRC cells appear to
be associated with intrinsic mitochondrial death path-
way. The treatment with FFAE of krill oil resulted in a
significant increase in ROS and MMP. This then acti-
vated caspase-9 and caspase-3 leading to DNA damage
and cellular apoptosis. The outcome of this study impli-
cates a possible clinical application of krill oil. Further
animal studies and human clinical trials are required to
validate the efficacy of krill oil on the prevention and
treatment of CRC.
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